VIDEO: Axitinib shows clinically meaningful treatment burden reduction in wet AMD
CHICAGO — In this Healio Video Perspective from the AAO meeting, David A. Eichenbaum, MD, discusses results from a phase 1 trial investigating axitinib for the treatment of neovascular age-related macular degeneration.
The axitinib intravitreal implant (Ocular Therapeutix) demonstrated a clinically meaningful treatment reduction compared with aflibercept, according to Eichenbaum. The implant also yielded stable visual acuity and anatomy.
“The pharmacodynamics that we see with axitinib support a treatment that would probably be able to be dosed every 9 to 12 months,” he said.
Collapse
Eichenbaum DA. Fifty-two-week sustained efficacy and treatment burden reduction with OTX-TKI in the U.S. phase 1 trial for nAMD. Presented at: American Academy of Ophthalmology meeting; Oct. 18-21, 2024; Chicago.
Read more about